Want to know more? Below, I highlight six useful reviews and articles about the rule.
I also provide info on two official (and free) CMS webinars happening later this week:
- For manufacturers on Wednesday, Feb. 10
- For pharmacies on Thursday, Feb. 11
STUFF TO READ
1) The Final AMP Rule: An Overview for Stakeholders, Arent Fox
2) Final ACA Medicaid Drug Pricing Rule Published: Changes to 5i, Bundling, RCP and Other Provisions Leave a Lot for Manufacturers to Consider, King & Spalding
3) The CMS Final Covered Outpatient Drug Rule Addresses Many Industry Concerns, Morgan Lewis
4) Deciphering the Final AMP Rule, Healthcare Distribution Management Association
5) Initial takeaways on the AMP final rule, CIS by Deloitte
6) Attorneys Have Concerns With Final Medicaid Drug Rule, Bloomberg BNA
Here are the two webinars that CMS announced yesterday and the official CMS descriptions.
1) Drug Manufacturers and Government Pricing/Programs
Wednesday, February, 10, 2016, 12:30 – 2:00 p.m. ET
1-844-396-8222 / PIN: 644 043 119
This webinar will be geared towards drug manufacturers and those with responsibilities or involvement in government pricing/programs. While we will provide a broad overview of the final rule with comment, the focus of this webinar will be manufacturer reporting requirements and rebate requirements including topics related to Average Manufacturer Price (AMP), best price, 5i drugs, authorized generics, covered outpatient drug definition, innovator multiple source drug and single source drug definitions, drugs approved exclusively for pediatric indications, and line extension drugs.
2) Pharmacy Industry
Thursday, February 11, 2016, 12:30 – 2:00 p.m. ET:
1-877-267-1577 / PIN: 995 608 816
This webinar will be geared toward the pharmacy industry including retail community pharmacies and pharmacy trade organizations. While we will provide a broad overview of the final rule with comment, the focus of this webinar will primarily be within the area of pharmacy reimbursement, including the Federal upper limits (FULs), Actual Acquisition Cost, Professional Dispensing Fee, and Reimbursement for Federal Discount Programs (340B and Federal Supply Schedule (FSS)).